EUROVAC: European vaccine effort against HIV/AIDS (cluster proposal, 8-4)

• Research unit: EU RFP
• Project number: 99.0471-6

Key words (English)

AIDS/HIV; vaccine; vaccinia; DNA; mucosal adjuvant;
Life Sciences; Medicine; Health; Safety; Scientific Research; Social Aspects

Alternative project number (English)

EU project number: QLK2-CT-1999-01321

Research programs (English)

EU-programme: 5. Frame Research Programme - 1.1.2 Control of infectious diseases

Short description (English)

See abstract

Further information (English)

Full name of research-institution/enterprise:
Institut suisse de recherche expérimentale sur le cancer ISREC

Partners and International Organizations (English)

Coordinator: CNRS, Lyon (F)

Abstract (English)

During the third year, four major projects were completed in Lausanne:
1/ We have established in mice that the recombinant modified Ankara vaccinia strains expressing the gag pol nef polygene administered by the nasal route is safe. A protocol to test safety of MVA/ NYVAC vaaccines adninistered by the nasal route has been accepted by the Delft ethical committee. The trial is starting on March 2003.
2/ Immunogenicity of recombinant NYVAC, MVA, SFV and DNA expressing clade B gag pol nef polygene was tested in HLA-A2 transgenic and C57BL/6 mice . All recombinant vaccines are immunogenic alone or in combination.
3/. A novel mucosal adjuvant, bacterial flagellin, has been shown to enhance both antibody and CTL production, to recruit antigen presenting cells into mucosal tissues and to modulate immune responses (Th2 polarization).
4/ Novel mucosal readouts have been developed to monitor CTL in vaginal tissues and are currently optimized and standardized.

References in databases (English)

Swiss Database: Euro-DB of the
State Secretariat for Education and Research
Hallwylstrasse 4
CH-3003 Berne, Switzerland
Tel. [phone]
Swiss Project-Number: 99.0471-6